Clinical trials: Monoclonal
HIV Infections
Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults
The purpose of this study is to evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected…
- Trial name
- NCT03387150
- Testing
- VRC07-523LS
- Where
- 7 sites in United States, Switzerland
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
- Trial name
- EMBODY4 (NCT01408576)
- Testing
- Epratuzumab
- Where
- 228 sites in United States, Australia and 23 more
- Volunteers
- 1,250 people
- Sponsor
- UCB Pharma
Lymphoma, Non-Hodgkin
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
Phase I/II, single-center, dose-escalation study of the safety, pharmacokinetics, dosimetry, and efficacy of TST/I-131 TST for the treatment of patients with chemotherapy-refractory or resistant low-grade, intermediate-grade, or…
- Trial name
- NCT01536561
- Testing
- Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire
Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with…
- Trial name
- NCT02340975
- Testing
- MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- MedImmune LLC
Stage IV Pancreatic Cancer
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
This randomized phase I/II trial is studying the side effects and best dose of monoclonal antibody therapy when given together with gemcitabine hydrochloride and erlotinib hydrochloride and to see how well they work compared with…
- Trial name
- NCT00617708
- Testing
- cixutumumab, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 146 sites in United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Background: Human immunodeficiency virus (HIV) affects the immune system. The main function of the immune system is protect you from infections and other diseases such as cancer.
- Trial name
- NCT03571204
- Testing
- 3BNC117 and 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
X-linked Hypophosphatemia
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
The objectives of the study are to: Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants Establish the safety profile of burosumab for the treatment of…
- Trial name
- NCT02163577
- Testing
- burosumab
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 52 people
- Sponsor
- Kyowa Kirin, Inc.
Lymphoma
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00553501
- Testing
- epratuzumab, rituximab
- Where
- 43 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Neoplasms
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Background: Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a person with prostate cancer and treats them in the laboratory.
- Trial name
- NCT01420965
- Testing
- CT-011 (Anti-PD1 Antibody), Sipuleucel-T (Provenge), Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Augusta University
Colorectal Cancer
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
The primary objective of this study is to compare the additive efficacy of SIM versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as measured by improvement in progression-free…
- Trial name
- NCT01479465
- Testing
- Simtuzumab, Leucovorin, Irinotecan
- Where
- 109 sites in United States, France and 5 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had an inadequate prior treatment…
- Trial name
- NCT00995449
- Testing
- KB003
- Where
- 11 sites in United States
- Volunteers
- 9 people
- Sponsor
- Humanigen, Inc.
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Healthy
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
To evaluate the safety and tolerability of raxibacumab in healthy subjects.
- Trial name
- NCT00639678
- Testing
- raxibacumab
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- Human Genome Sciences Inc.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
A Phase I/II Study of Intratumoral Injection of SD-101
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02254772
- Testing
- Ipilimumab, SD-101, Radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Robert Lowsky
Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma
Avelumab for People With Recurrent Respiratory Papillomatosis
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. It can cause voice changes, airway compromise, pulmonary lesions, and cancers.
- Conditions
- Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Respiratory Papillomatosis
- Trial name
- NCT02859454
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
- Trial name
- NCT00942422
- Testing
- defined green tea catechin extract, gene expression analysis, protein analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer.
- Trial name
- NCT00702923
- Testing
- Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (tremelimumab), Bicalutamide, CP-675,206
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Arthritis, Osteoarthritis
Tanezumab in Osteoarthritis of the Knee
Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.
- Trial name
- NCT00733902
- Testing
- tanezumab
- Where
- 82 sites in United States
- Volunteers
- 697 people
- Sponsor
- Pfizer